Use of arginine as an lymphokine synergist
US4883661A · kind A · utility
13Cited by
1References
9Claims
0Family size
Inventors
Key dates
| Filing date | Oct 9, 1987 |
| Grant date | Nov 28, 1989 |
| Priority date | — |
| Expiry date | Oct 9, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/811
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It has been found that arginine serves to increase the receptivity of cells to lymphokines such as interleukin-2 and interferon. An improved method for treating a mammal with one or more lymphokines is disclosed wherein said improvement comprises administering said one or more lymphokines to said mammal in combination with an amount of arginine effective to increase the receptivity of cells of said mammal to said one or more lymphokines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.